Serotonergic agents in the treatment of fibromyalgia syndrome
Lisa J Miller1, Kristy L Kubes
1Pharmacy Department, Memorial Hermann Southwest Hospital, Houston, TX 77074, USA. lisa_miller@mhhs.org
Objective:
To evaluate literature that discusses the treatment of fibromyalgia syndrome (FMS) with agents that involve the neurotransmitter serotonin.
Data Sources:
Biomedical literature accessed through MEDLINE (1966-August 2001) and International Pharmaceutical Abstracts.
Data Synthesis:
The cause and pathophysiology of FMS remain elusive, although abnormalities in the serotonin pathway have been implicated. Several serotonergic agents have been studied for use in FMS. Trials and case reports focusing on the use of newer agents: the selective serotonin reuptake inhibitors, venlafaxine and tramadol, were reviewed.
Conclusions:
Current research suggests that the serotonergic agents may reduce at least some of the symptoms of FMS. However, medications that act on multiple neurotransmitters may prove to be more effective in symptom management. Additional long-term studies are required in order to validate these results.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:25Antidepressant Drugs: Overview
01:27G Protein-coupled Receptors